HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

taletrectinib

type I ROS1-NTRK inhibitor

Also Known As:

3-(4-((2R)-2-aminopropoxy)phenyl)-N-((1R)-1-(3-fluorophenyl)ethyl)imidazo(1,2-b)pyridazin-6-amine;hexanedioic acid

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - taletrectinib: 2
  - Pyridazines: 11
    - taletrectinib: 2

Experts

1.	Borazanci, Erkut: 1 article (01/2020)
2.	Deng, Chenhui: 1 article (01/2020)
3.	Fan, Frank: 1 article (01/2020)
4.	Gao, Yanfei: 1 article (01/2020)
5.	Hanzawa, Hiroyuki: 1 article (01/2020)
6.	Isoyama, Takeshi: 1 article (01/2020)
7.	Jänne, Pasi A: 1 article (01/2020)
8.	Katayama, Ryohei: 1 article (01/2020)
9.	Li, Meijing: 1 article (01/2020)
10.	Madison, Russell: 1 article (01/2020)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors." 01/01/2023 - "Data from a regional phase II clinical trial showed that taletrectinib is well tolerated, effective for patients who have never taken a ROS1 targeted therapy and inhibits ROS1+ NSCLC for patients whose cancer has developed some types of resistance to these drugs. " 01/01/2023 - "Here we describe the rationale and design of TRUST-II, a global phase II study of taletrectinib in patients with locally advanced/metastatic ROS1+ non-small-cell lung cancer and other ROS1+ solid tumors. " 01/01/2023 - "TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors."
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2023 - "Here we describe the rationale and design of TRUST-II, a global phase II study of taletrectinib in patients with locally advanced/metastatic ROS1+ non-small-cell lung cancer and other ROS1+ solid tumors. " 01/01/2023 - "TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors."
3.	Neoplasm Metastasis (Metastasis) 01/01/2023 - "Taletrectinib was designed to: improve efficacy; overcome resistance to first-generation ROS1 inhibitors; and address brain metastasis while conferring fewer neurological adverse events. "

Related Therapies and Procedures

1.	Therapeutics